Hidradenitis suppurativa and functional disability

Hidradenitis supurativa y su discapacidad funcional

Main Article Content

Walter Gabriel Chaves Santiago
Paula Andrea Villarreal Marín

Abstract

Introduction: hidradenitis suppurativa (HS) is a rare disease with increased prevalence. Clinical manifestations often start at puberty. Early lesions can mimic other dermatological disorders which delays diagnosis and increases the risk of progression, leading to extensive lesions over the body, limited daily activities and a negative psychological impact. There are some risk factors although they are not very specific. The diagnosis is based on identifying the lesions and their typical distribution. Some severity and prognosis scales for HS may be useful. Case presentation: this is a case of long-standing hidradenitis suppurativa associated with a genetic component, which has received numerous treatments, but none has been effective in controlling the condition. Currently the disease stage is advanced with systematic involvement and decreased quality of life. She is being treated with tumor necrosis factor- alpha inhibitors monoclonal antibodies.  Conclusions: it is paramount to be aware of this pathology, to suspect it and exclude a differential diagnosis, to provide timely therapy and thus prevent progression and complications associated with lasting reduction in quality of life.

Keywords:

Downloads

Download data is not yet available.

Article Details

Author Biography

Walter Gabriel Chaves Santiago, Fundación Universitaria de Ciencias de la Salud

Jefe del Servicio de Medicina Interna Hospital de San José. Profesor Asociado Fundación Universitaria de Ciencias de la Salud.

References

Goldburg SR, Strober BE, Payette MJ. Hidradenitis Suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1054-1058. https://doi.org/10.1016/j.jaad.2019.0 8.090.

Liy-Wong C, Pope E, Lara-Corrales I. Hidradenitis suppurativa in the pediatric population. J Am Acad Dermatol. 2015;73(5 Suppl 1):38-41, doi: http://dx.doi.org/10.1016/j.jaad.2015.07.051

Martorell A, García-Martínez FJ, Jiménez-Gallo D, Pascual JD, Pereyra-RodriguezeL J, Salgado L, Vilarrasa E. Actualización en hidradenitis supurativa (I): epidemiología, aspectos clínicos y definición de severidad de la enfermedad. ACTAS Dermo-Sifiliográficas. 2015;105(7):703-715. http://dx.doi.org/10.1016/j.ad.2015.06.004.

Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Current and emerging treatments. J Am Acad Dermatol. 2020;82(5):1061-1082. https://doi.org/10.1016/j.jaad.2019.08.089.

Sabat R, Jemec G, Matusiak L, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. doi: https://doi.org/10.1038/s41572-020-0149-1.

Brown L. ClinicalKey. J Med Libr Assoc. 2013;101(4):342–3. https://doi.org/10.3163/1536-5050.101.4.023

Napolitano M, Mastroeni S, Fusari R, Mazzanti C, Ciccone D, Pallotta S, Sampogna F, Fania L, Abeni D. The International Hidradenitis Suppurativa Severity Score System (IHS4) is a valuable tool to assess gender-associated differences. Eur J Dermatol. 2020;30(2):201–203. https://doi.org/10.1684/ejd.2020.3743

Citado por